{"id":53087,"date":"2023-01-19T13:02:10","date_gmt":"2023-01-19T12:02:10","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\/"},"modified":"2023-01-19T13:02:10","modified_gmt":"2023-01-19T12:02:10","slug":"avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\/","title":{"rendered":"Avivagen Announces Foundational Scientific and Commercial Evidence of OxC-Beta\u2122 Product Published in Peer-Reviewed Journal"},"content":{"rendered":"
\n

\n-Publication showcases the cumulative understanding to-date of Avivagen\u2019s product from both a scientific and real world application perspective<\/i>\n<\/p>\n

\n-Product\u2019s value and safety has been shown through use in many settings, under differing conditions and in millions of animals<\/i>\n<\/p>\n

OTTAWA, Ontario–(BUSINESS WIRE)–Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (\u201cAvivagen\u201d), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that its scientific team has just published a peer-reviewed paper describing the discovery, natural occurrence, scientific significance, commercial livestock applications and safety of OxBC, the active ingredient of OxC-beta\u2122 Livestock.\n<\/p>\n

\nThe peer-reviewed paper, entitled “Oxidized \u03b2-Carotene Is a Novel Phytochemical Immune Modulator That Supports Animal Health and Performance for Antibiotic-Free Production<\/i>” appears in a special edition of the journal \u201cAnimals\u201d dedicated to the topic of alternatives to antibiotics. The paper reports key scientific evidence regarding OxBC mode of action including the fact that OxBC, unlike antibiotics, does not have any direct anti-bacterial activity and thus does not contribute to the potential rise of antibiotic resistant bacteria.\n<\/p>\n

\nCommercially salient points reported in the paper include results from multiple research trials with OxC-beta\u2122 Livestock in poultry, swine, and dairy cows supplemented with low parts-per-million in-feed levels of OxBC showing economically significant benefits over and above those of feeds containing regular vitamin and mineral premixes. The paper also highlights regulatory approvals and successful commercial use in several countries as strong supporting evidence for the safety and viability of OxC-beta\u2122 Livestock as an alternative for the use of in-feed antibiotics as well as its ability to provide tangible benefits in applications where antibiotic usage is not permitted. Of note, the paper also disclosed that as of mid-2022, OxBC has been used commercially in the form of OxC-beta\u2122 Livestock in various countries as a feed additive in approximately 16 million piglets, 94,000 sows, and 19.6 million poultry, and as a supplement for 12,000 dairy cows.\n<\/p>\n

\nPlease refer to the full content of the peer reviewed publication which can be found on the link: https:\/\/www.mdpi.com\/2076-2615\/13\/2\/289\/pdf<\/a>\n<\/p>\n

\nAbout Avivagen
\n
<\/b>Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com<\/a>. The contents of the website are expressly not incorporated by reference in this press release.\n<\/p>\n

\nAbout OxC-beta\u2122 Technology and OxC-beta\u2122 Livestock
\n
<\/b>Avivagen\u2019s OxC-beta\u2122 technology is derived from Avivagen discoveries about \u03b2-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta\u2122 Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, Vietnam and Malaysia.\n<\/p>\n

\nAvivagen\u2019s OxC-beta\u2122 Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta\u2122 Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.\n<\/p>\n

\nForward Looking Statements
\n
<\/b>This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions \u201caim\u201d, \u201canticipate\u201d, \u201cappear\u201d, \u201cbelieve\u201d, \u201cconsider\u201d, \u201ccould\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cif\u201d, \u201cintend\u201d, \u201cgoal\u201d, \u201chope\u201d, \u201clikely\u201d, \u201cmay\u201d, \u201cplan\u201d, \u201cpossibly\u201d, \u201cpotentially\u201d, \u201cpursue\u201d, \u201cseem\u201d, \u201cshould\u201d, \u201cwhether\u201d, \u201cwill\u201d, \u201cwould\u201d and similar expressions.<\/i>\n<\/p>\n

\nStatements set out in this news release relating to the potential positive impacts expected to arise from the publication of the above-reference article, the future growth and prospects for Avivagen, and the possibility for OxC-beta\u2122 Livestock to replace antibiotics in livestock feeds as growth promoters are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen\u2019s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics as growth promoters in livestock feeds due to many factors, many of which are outside of Avivagen\u2019s control. Orders may be cancelled for many reasons outside of Avivagen\u2019s control. Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen\u2019s most recent management\u2019s discussion and analysis of financial condition available at www.SEDAR.com<\/a>. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.<\/i>\n<\/p>\n

\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/i>\n<\/p>\n

\nCopyright \u00a9 2023 Avivagen Inc. OxC-beta\u2122 is a trademark of Avivagen Inc.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAvivagen Inc.
\n
Drew Basek
\n
Director of Investor Relations
\n
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
\n
Phone: 416-540-0733
\n
E-mail: d.basek@avivagen.com<\/a>\n<\/p>\n

\nKym Anthony
\n
Chief Executive Officer
\n
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
\n
Head Office Phone: 613-949-8164
\n
Website: www.avivagen.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

-Publication showcases the cumulative understanding to-date of Avivagen\u2019s product from both a scientific and real world application perspective -Product\u2019s value and safety has been shown through use in many settings, under differing conditions and in millions of animals OTTAWA, Ontario–(BUSINESS WIRE)–Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (\u201cAvivagen\u201d), a life sciences corporation focused on developing and commercializing products … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53087","6":"format-standard","7":"category-industry"},"yoast_head":"\nAvivagen Announces Foundational Scientific and Commercial Evidence of OxC-Beta\u2122 Product Published in Peer-Reviewed Journal - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avivagen Announces Foundational Scientific and Commercial Evidence of OxC-Beta\u2122 Product Published in Peer-Reviewed Journal - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"-Publication showcases the cumulative understanding to-date of Avivagen\u2019s product from both a scientific and real world application perspective -Product\u2019s value and safety has been shown through use in many settings, under differing conditions and in millions of animals OTTAWA, Ontario–(BUSINESS WIRE)–Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (\u201cAvivagen\u201d), a life sciences corporation focused on developing and commercializing products ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-19T12:02:10+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Avivagen Announces Foundational Scientific and Commercial Evidence of OxC-Beta\u2122 Product Published in Peer-Reviewed Journal\",\"datePublished\":\"2023-01-19T12:02:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\\\/\"},\"wordCount\":975,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\\\/\",\"name\":\"Avivagen Announces Foundational Scientific and Commercial Evidence of OxC-Beta\u2122 Product Published in Peer-Reviewed Journal - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-01-19T12:02:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avivagen Announces Foundational Scientific and Commercial Evidence of OxC-Beta\u2122 Product Published in Peer-Reviewed Journal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avivagen Announces Foundational Scientific and Commercial Evidence of OxC-Beta\u2122 Product Published in Peer-Reviewed Journal - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\/","og_locale":"en_US","og_type":"article","og_title":"Avivagen Announces Foundational Scientific and Commercial Evidence of OxC-Beta\u2122 Product Published in Peer-Reviewed Journal - Pharma Trend","og_description":"-Publication showcases the cumulative understanding to-date of Avivagen\u2019s product from both a scientific and real world application perspective -Product\u2019s value and safety has been shown through use in many settings, under differing conditions and in millions of animals OTTAWA, Ontario–(BUSINESS WIRE)–Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (\u201cAvivagen\u201d), a life sciences corporation focused on developing and commercializing products ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-19T12:02:10+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Avivagen Announces Foundational Scientific and Commercial Evidence of OxC-Beta\u2122 Product Published in Peer-Reviewed Journal","datePublished":"2023-01-19T12:02:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\/"},"wordCount":975,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\/","url":"https:\/\/pharma-trend.com\/en\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\/","name":"Avivagen Announces Foundational Scientific and Commercial Evidence of OxC-Beta\u2122 Product Published in Peer-Reviewed Journal - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-01-19T12:02:10+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/avivagen-announces-foundational-scientific-and-commercial-evidence-of-oxc-beta-product-published-in-peer-reviewed-journal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Avivagen Announces Foundational Scientific and Commercial Evidence of OxC-Beta\u2122 Product Published in Peer-Reviewed Journal"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53087"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53087\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}